Blackstone (BX) Commits $400 Million With Teva to Advance Duvakitug Clinical Development

Blackstone Inc. (NYSE:BX) is one of the 10 Best Asset Management Stocks to Buy Right Now.

Blackstone (BX) Commits $400 Million With Teva to Advance Duvakitug Clinical Development Top 100 Places Where the Rich People Own Real Estate

On March 3, 2026, Blackstone Life Sciences, a specialized life sciences investment platform of Blackstone Inc. (NYSE:BX), entered a $400 million strategic funding agreement with Teva Pharmaceuticals. The agreement aimed at accelerating the clinical development of duvakitug, a monoclonal antibody targeting TL1A. It is currently in Phase 3 trials for ulcerative colitis and Crohn’s disease, following the success of Phase 2b data. Blackstone Inc. (NYSE:BX)’s investment is spread over four years, and the firm will receive regulatory milestones and low single-digit global royalties upon FDA approval. Paris Panayiotopoulos, Senior Managing Director at Blackstone Life Sciences, gave the following statement.

Duvakitug has the potential to be a best-in-class therapy in a large and growing space, and the Teva and Sanofi teams are well positioned to develop and commercialize this important medicine.

In a more recent development, on March 5, 2026, Barclays analyst Benjamin Budish reinstated coverage of Blackstone with an Equal Weight rating and a $126 price target. Following a brief restriction period, the firm is covering the stock with unchanged ratings and earnings estimates.

Founded in 1985, Blackstone Inc. (NYSE:BX) is the world’s largest alternative asset manager operating from its headquarters in New York.

While we acknowledge the risk and potential of BX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than BX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 10 Best Stocks to Buy According to Elliott Investment Management and 10 Best Stocks to Invest in During a Recession

Disclosure: None.  Follow Insider Monkey on Google News.